Gregory P. Kalemkerian

Gregory P. Kalemkerian

Auto-generated profile, based on publicly available information

Gregory P. Kalemkerian

University of Michigan, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HKHumera Khurshid
Humera Khurshid
NINofisat Ismaila
Nofisat Ismaila
JBJessica Bian
Jessica Bian
RDRaetasha Dabney
Raetasha Dabney
MDMillie Das
Millie Das
GKGregory P. Kalemkerian
Gregory P. Kalemkerian
PURPOSE: To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. METHODS: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 95 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer. Additional information is available at www.asco.org/thoracic-cancer-guidelines .

26 March 2026 in Journal of Clinical Oncology
Verified
Journal Article
Open access
BBBenjamin Besse
Benjamin Besse
VSVivek Subbiah
Vivek Subbiah
GCGiuseppe Curigliano
Giuseppe Curigliano
DBDaniel Bowles
Daniel Bowles
RDRobert C. Doebele
Robert C. Doebele
JGJustin F. Gainor
Justin F. Gainor
RET fusions appear in 1%-2% of non–small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385 ) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET -altered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion–positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion–positive NSCLCs, confirming previous findings with longer follow-up.

1 June 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
HKHumera Khurshid
Humera Khurshid
NINofisat Ismaila
Nofisat Ismaila
MDMillie Das
Millie Das
SKSwati Kulkarni
Swati Kulkarni
RMRami Manochakian
Rami Manochakian
GKGregory P. Kalemkerian
Gregory P. Kalemkerian

20 August 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMikkael A. Sekeres
Mikkael A. Sekeres
GAGregory A. Abel
Gregory A. Abel
TGTimothy Gilligan
Timothy Gilligan
SGStephanie L Graff
Stephanie L Graff
GKGregory P. Kalemkerian
Gregory P. Kalemkerian
JRJamie Cathleen Riches
Jamie Cathleen Riches

1 May 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
PSP.D. Soni
P.D. Soni
PBP.S. Boonstra
P.S. Boonstra
MSM. Schipper
M. Schipper
LBL. Bazzi
L. Bazzi
RDR.T. Dess
R.T. Dess
SJS. Jolly
S. Jolly